SCHEMBL10138486

SCHEMBL10138486

COc1ccc(SNc2nc(-c3ccccc3)nn2C)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 3/20 0.45
USP2 O75604 2/20 0.45
MAPK1 P28482 2/20 0.45
KLK7 P49862 1/20 0.45
MAPK10 P53779 1/20 0.45
KLK5 Q9Y337 1/20 0.45
PSEN1 P49768 3/20 0.44
PSEN2 P49810 3/20 0.44
APH1B Q8WW43 3/20 0.44
NCSTN Q92542 3/20 0.44
APH1A Q96BI3 3/20 0.44
PSENEN Q9NZ42 3/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
NR1H2 P55055 1/20 0.42
NR1H3 Q13133 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10138511 0.79 ALDH1A1 (0.41) KMT2AKDM4EHSD17B10USP2MAPK1
SCHEMBL10138490 0.79 NR1H3 (0.53) KMT2AMAPK1NPC1RAB9ANR1H2
SCHEMBL10119718 0.78 KMT2A (0.58) KMT2AKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL14265882 0.77 ADORA3 (0.52) KMT2AKDM4EHSD17B10USP2MAPK1
SCHEMBL633322 0.76 CA12 (0.56) KMT2AMAPK1ALDH1A1MAPTMEN1
SCHEMBL14265513 0.70 SMN1; SMN2 (0.47) KMT2AKDM4EHSD17B10USP2MAPK1
SCHEMBL12909523 0.70 NR1H3 (0.59) KMT2AHSD17B10NPC1RAB9ANR1H2
SCHEMBL10139034 0.69 NR1H3 (0.58) KMT2AHSD17B10USP2NPC1RAB9A
SCHEMBL8303302 0.67 NR1H2 (0.59) KMT2AKDM4EHSD17B10USP2MAPK1
SCHEMBL12890482 0.66 NR1H3 (0.54) KMT2AHSD17B10NPC1RAB9ANR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046324-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED 2012-02-23 US disclosed
US-20080070937-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE J. DAVID GLADSTONE INSTITUTES 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070937-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE KMO, KYNU, TDO2 KMT2A 1046/4885KDM4E 1039/4885HSD17B10 198/4885
US-20120046324-A1 SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE KMO, KYNU, TDO2 KMT2A 1046/4885KDM4E 1039/4885HSD17B10 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.